Part of the Keystone Symposia Conference Series
Phosphoinositides have been recognized since the 1980s as important regulatory lipids supporting signal transduction from G protein-coupled receptors and receptor tyrosine kinases. The discovery of PI 3-kinases and their roles in carcinogenesis and immune regulation has created a fertile ground for translational expansion of the phosphoinositide field with a focus on cancer and inflammation. Most of these advances focused on Class I PI3Ks and PIP3-mediated signaling. However, research on other PI kinases and phosphoinositides has expanded substantially over the years. Class II and -III PI 3-kinases and less characterized 3-phosphorylated phosphoinositides are now rapidly emerging as key controllers of development, trafficking, nutrition-sensing and autophagy.
Furthermore, phosphoinositides different from the 3-phosphorylated species are gaining momentum in many aspects of cell physiology and pathology. Exciting new developments include PI 4-kinases controlling vesicular trafficking and non-vesicular lipid transfer between membrane contacts, and new details are emerging on the role of inositol lipid phosphatases in trafficking, endocytosis and ciliary function. The recently recognized roles of PI 4-kinases as obligate host factors for certain RNA viruses, and their importance in parasitic organisms such as Plasmodium falciparum or Legionella pneumophila, have raised significant interest from pharmaceutical companies that now focus on inositol lipids other than the products of PI 3-kinases.
By expanding our knowledge of phosphoinositides beyond class I PI3K products, this Keystone Symposia meeting represents a unique opportunity to bolster the growing interest in these under-explored avenues with a strong potential for translational impact.
MMV's Cristina Donini will be speaking about MMV048, a Plasmodium PI4K Inhibitor as Potential Malarial Treatment